Mirador Therapeutics – a company founded by Mark C. McKenna and led by several former executives of Prometheus Biosciences (acquired in 2023 by Merck for $10.8 billion) – launched this month. Mirador has raised over $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount. Other premier life sciences investors also joined, including Fidelity Management & Research Company, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Sanofi Ventures, Woodline Partners, Venrock Healthcare Capital Partners, RTW Investments and Alexandria Venture Investments.
Mirador plans to transform precision medicine for immune-mediated inflammatory and fibrotic diseases by rapidly advancing multiple programs using its proprietary Mirador360 development engine.
The company’s focus is on developing first-in-class or best-in-class precision medicines. To accelerate development, Mirador utilizes Mirador360, its proprietary precision development engine that uses human genetics and data science breakthroughs.
Mirador360 is purpose-built to coordinate millions of patient molecular profiles to discover and validate genetic associations to immuno-fibrotic diseases, identify novel therapeutic targets, and elucidate target-target interactions and optimal target-target pairs for potential combination therapies. It also enables Mirador to develop diagnostics and stratify heterogeneous patient populations for precise clinical development.
KEY QUOTES:
“At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy. The industry has only scratched the surface of utilizing advances in human genetics – coupled with exponential progress in machine learning – to accelerate the development of precision therapies for patients who need them the most. With a proven team, distinguished board of directors, leading healthcare investors and proprietary data-driven approach, we aim to create a leading precision medicine company at scale to provide important new treatment options for patients.”
– Mark C. McKenna, chairman and CEO of Mirador
“The I&I field is in need of better, novel therapeutics as well as new R&D approaches that target enriched patient populations for improved probability of success in the clinic. The Mirador team has an outstanding track record of success in precision immunology, and we are well on our way to building a company that will make a lasting impact on the lives of millions of patients suffering from a broad range of immune-mediated inflammatory and fibrotic diseases.”
– Kristina Burow, Mirador board member and managing director of ARCH Venture Partners
